BioVenture

RootPath Genomics, Inc. is a biotechnology company founded in 2017 and headquartered in Cambridge, Massachusetts. The company specializes in developing a next-generation T-cell therapy platform that integrates precision medicine with cancer immunotherapy. By focusing on the analysis and manipulation of individual immune cells, RootPath aims to enhance immune responses and improve cell therapy efficacy. Its innovative technologies allow for precise monitoring and modulation of the immune system, which is intended to revolutionize the diagnosis and treatment of cancer.

Macrolux Medical is a medical technology company that specializes in endoscopic interventional solutions. It focuses on developing devices for both diagnosis and treatment across various medical fields, including urology, respiratory, and digestive health. By promoting these innovative solutions to a wide range of medical customers, Macrolux aims to enhance patient outcomes through earlier detection and improved treatment options. The company's commitment to advancing endoscopic therapy positions it as a key player in the medical device sector.

Secretech is a research and development-driven biotechnology company focused on creating biomarkers and cellular exosomes. It specializes in developing a molecular detection technology platform designed to offer innovative solutions across scientific, clinical, and drug discovery sectors. The company is dedicated to advancing a new generation of molecular detection methods, integrated with advanced computational biology algorithms. This approach enables Secretech to deliver robust proteomics analysis tools that facilitate the rapid discovery of new molecular markers.

Shenzhen CardioACC Ltd specializes in advanced cardiovascular interventional, natural cavity imaging and advanced diagnostic procedures.

Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterol monitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.

Xiguang Bio focuses on the production of diagnostic reagents and provides chemiluminescent raw materials and overall system technology solutions.

Suzhou Panomic Biomedical Technology Co., Ltd. (BioNovoGene) was founded in Suzhou Industrial Park Bio-Nano Park in 2013. It is a leading high-tech enterprise focusing on metabolomics in China. Since its establishment, it has established a complete metabolomics detection and analysis platform - PanomicTM / Bionovogene, including metabolite preprocessing platform, high-resolution mass spectrometry analysis platform, and metabolomics data analysis with independent intellectual property rights The system has perfect biomarker discovery capabilities and clinical application capabilities. The company's scientific research team has a rich background, covering biochemistry, bioinformatics, epidemiology and biostatistics, computer science, etc., and has a consultant team composed of top scientists and clinicians.

Chromai is a company specializing in high-performance intelligent liquid chromatography and medical diagnostic solutions. It focuses on independent innovation and aims to contribute to the revitalization of the national industry. Chromai develops advanced medical molecular diagnostics and testing technologies that streamline the diagnostic process. By leveraging a combination of artificial intelligence, Big Data, and Internet of Things (IoT) technologies alongside leading analysis and detection methods, the company is dedicated to enhancing the fields of health in vitro diagnostics (IVD), environmental protection, and scientific instruments. This commitment enables medical users to achieve simplified and efficient diagnostic and testing analyses.

Innovision is a company that specializes in developing auxiliary diagnosis and treatment systems tailored for endoscopy centers in hospitals. By leveraging artificial intelligence deep learning technology, Innovision processes digestive endoscopy image data to assist in medical imaging-assisted diagnosis of the digestive system. This innovative approach helps hospitals enhance work efficiency and alleviate the workload on endoscopy doctors, ultimately reducing the need for redundant labor.

Human Zhizao is a technology platform that provides comprehensive diagnostic solutions. They provide clinical customers with a parallel, full-automatic multiple flow cytometry fluorescence detection platform and supporting reagents. They provide customer service. The flow fluorescence luminescence technology is a new generation of throughput detection and analysis platform integrating flow analysis, laser analysis, digital signal processing, and other technologies. They involve projects that require the joint detection of multiple indicators, such as autoantibodies, allergens, cytokines, etc.

Hanchao Pharmaceutical is a biopharmaceutical company that specializes in the development and production of medical equipment and solutions for the biomedical industry. The company's core focus is on providing single-use bioprocessing solutions, with a particular emphasis on biomedical production technology. Hanchao independently designs, manufactures, and sells a range of equipment and consumables, catering to the industrialization stage of various biomedical fields, including antibodies, vaccines, antibody-drug conjugates (ADCs), and cell and gene therapies (CGTs).

Future Vision is a visual health service organization based in Shanghai, specializing in the prevention and control of myopia, amblyopia rehabilitation training, and medical optometry for children aged 3 to 16. The company utilizes advanced North American optometry technology to deliver its services, aiming to address the growing concerns of visual health among children. By focusing on early intervention and comprehensive eye care, Future Vision seeks to improve the visual outcomes for its young clientele.

Ehomepoct is a healthcare management company based in Changsha, China, specializing in the manufacture of diagnostic test kits. The company produces a range of products, including pregnancy tests, inflammation tests, menstrual period tests, and early embryo testing kits. In addition to its diagnostic offerings, Ehomepoct integrates artificial intelligence into its healthcare solutions, enhancing rapid diagnosis and health management services. Through its innovative approach, Ehomepoct aims to improve medical treatment and facilitate better health outcomes.

NeuroEchos, established in 2017, specializes in functional neurosurgery with a focus on precise electroencephalogram (EEG) technology. The company offers integrated diagnostic and treatment solutions for diseases resulting from abnormal nervous system discharges. NeuroEchos utilizes artificial intelligence-assisted decision-making software to accurately interpret EEG waves, enhancing the diagnosis process. Additionally, they contribute to neuroscience research through their advanced deep brain electrodes.

Beijing Changmugu Medical Technology Co., Ltd. is a healthcare start-up that specializes in developing artificial intelligence-powered solutions for medical and surgical applications. Based in Beijing, China, the company focuses on enhancing orthopedic procedures through advanced technology. It offers a range of services including AI-assisted diagnosis, individualized surgical planning, 3D printing for patient-specific instrumentation, and post-operative evaluation. By leveraging deep learning algorithms, Changmugu Medical aims to improve the precision and safety of orthopedic surgeries, ultimately providing patients with more secure and reliable treatment options.

Hopstem Biotechnology LLC is a Houston-based company that focuses on the development of neural stem cell technology and stem cell therapies specifically for neurological disorders. Established in 2019, the company specializes in the neural differentiation, cell banking, and cell engineering of human induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs). By leveraging its advanced technologies, Hopstem aims to enhance biomedical research and improve diagnostic and therapeutic options for various neurological conditions. Through its innovative approaches, the company seeks to provide effective treatment solutions for patients suffering from these disorders.

Bioligo, officially known as Shanghai Bailige Biotechnology Co., Ltd., is a biotechnology company specializing in the provision of high-quality DNA synthesis and sequencing services. The company focuses on serving the genetic and molecular diagnostics sector, which is integral to the field of precision medicine. Bioligo offers a range of products, including DNA primers, fluorescently labeled probes, and RNA synthesis products. Additionally, they supply essential materials for next-generation sequencing library construction, such as adapters, blocking agents, and target capture probes. By addressing critical gaps in raw materials, Bioligo supports its downstream customers in the in vitro diagnostic industry, enhancing their capabilities in precision medicine applications.

Guangzhou Creative Biosciences, established in Guangzhou, China, specializes in the research, development, production, and sales of diagnostic kits for colorectal cancer screening. Their primary product is a non-invasive fecal DNA screening kit, which enables early detection of colorectal cancer by interpreting genetic abnormalities in feces. Additionally, the company offers diagnostic kits and equipment for lung cancer.

Hopstem Biotechnology LLC is a Houston-based company that focuses on the development of neural stem cell technology and stem cell therapies specifically for neurological disorders. Established in 2019, the company specializes in the neural differentiation, cell banking, and cell engineering of human induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs). By leveraging its advanced technologies, Hopstem aims to enhance biomedical research and improve diagnostic and therapeutic options for various neurological conditions. Through its innovative approaches, the company seeks to provide effective treatment solutions for patients suffering from these disorders.

Suzhou Panomic Biomedical Technology Co., Ltd. (BioNovoGene) was founded in Suzhou Industrial Park Bio-Nano Park in 2013. It is a leading high-tech enterprise focusing on metabolomics in China. Since its establishment, it has established a complete metabolomics detection and analysis platform - PanomicTM / Bionovogene, including metabolite preprocessing platform, high-resolution mass spectrometry analysis platform, and metabolomics data analysis with independent intellectual property rights The system has perfect biomarker discovery capabilities and clinical application capabilities. The company's scientific research team has a rich background, covering biochemistry, bioinformatics, epidemiology and biostatistics, computer science, etc., and has a consultant team composed of top scientists and clinicians.

Synaptic Medical Inc. is a medical device company dedicated to developing and commercializing innovative products aimed at treating cardiac arrhythmias and other cardiovascular diseases. Established in 2005 and headquartered in St. Paul, Minnesota, the company also maintains an office in Beijing, China. Synaptic Medical specializes in cardiac electrophysiology, offering a range of products including bipolar pacing systems, fixed curve and deflectable diagnostic catheters, pulmonary vein mapping catheters, and ablation devices. The company's focus is on creating unique, cost-effective, and clinically advanced technologies that enhance treatment options for physicians and their patients.

Beijing Changmugu Medical Technology Co., Ltd. is a healthcare start-up that specializes in developing artificial intelligence-powered solutions for medical and surgical applications. Based in Beijing, China, the company focuses on enhancing orthopedic procedures through advanced technology. It offers a range of services including AI-assisted diagnosis, individualized surgical planning, 3D printing for patient-specific instrumentation, and post-operative evaluation. By leveraging deep learning algorithms, Changmugu Medical aims to improve the precision and safety of orthopedic surgeries, ultimately providing patients with more secure and reliable treatment options.

Yingsheng Biotechnology Co., Ltd., established in 2009, specializes in the development of in vitro diagnostic reagents and medical equipment focused on maternal and child health, neonatal genetic diseases, metabolic disorders, and birth defects. The company offers a diverse product line that includes 45 innovative screening reagents for genetic metabolic diseases, deaf genetic testing kits, vitamins determination reagents, and an HLA-B27 detection kit. Yingsheng also provides advanced diagnostic technologies such as a mass spectrometer automatic intelligent processing platform and ultra-high performance liquid chromatography tandem mass spectrometry detection systems. Through its innovative products, Yingsheng aims to facilitate early detection of genetic conditions, promoting timely intervention and better health outcomes for patients.

GensKey is a medical diagnostic service provider specializing in genetic testing for pathogen diagnosis. The company utilizes high-throughput sequencing technology combined with intelligent algorithm analysis to address challenges associated with traditional diagnostic methods, such as low detection rates, lengthy processes, and accuracy issues. By improving the timeliness and precision of pathogen diagnosis, GensKey enables patients suffering from severe infections to receive prompt and reliable diagnoses, thereby enhancing the potential for effective treatment and recovery.

Zhejiang Pushikang Biotechnology offer In-vitro diagnostics solutions.

X-ABT is a tech enterprise that provides solutions for pathogenic microorganism detection in the medical and health fields. The company focuses on providing complete solutions for the detection of infectious pathogens in the medical and health field. They develop and produce systems for disease control, prevention, clinical hospitals, and entry-exit customs. X-ABT also provides clinical marketing and sales services to help medical workers and serve patients.

Ruixun Biotech is a healthcare company that provides biotechnology. Ruixun Biotech combines microfluidics, optics, precision instruments, electronic engineering, and biochemical technologies to create upstream equipment and consumables for molecular diagnosis and genetic testing. They released a number of products, including the digital PCR apparatus DropX-2000 and more than 50 different RUO detection kits.

Founded in 2015, DiaMonTech specializes in developing non-invasive medical diagnostic devices. Its proprietary photo-thermal detection technology enables accurate glucose level measurements without finger pricking or blood samples.

Antai Kangcheng is a research and development company specializing in tumor electric field treatment technology, particularly aimed at addressing glioblastoma multiforme. The company is dedicated to creating innovative treatment methods and equipment for tumor management and central nervous system injury rehabilitation. Antai Kangcheng has developed a precise treatment planning system that integrates biophysical models with multimodal imaging systems, allowing for personalized treatment solutions tailored to the needs of Chinese patients. Furthermore, the company has achieved the visualization of intracranial electric field strength and can effectively manage electro-nodes to track tumors, enabling patients to receive effective treatment at a lower cost.

Yingsheng Biotechnology Co., Ltd., established in 2009, specializes in the development of in vitro diagnostic reagents and medical equipment focused on maternal and child health, neonatal genetic diseases, metabolic disorders, and birth defects. The company offers a diverse product line that includes 45 innovative screening reagents for genetic metabolic diseases, deaf genetic testing kits, vitamins determination reagents, and an HLA-B27 detection kit. Yingsheng also provides advanced diagnostic technologies such as a mass spectrometer automatic intelligent processing platform and ultra-high performance liquid chromatography tandem mass spectrometry detection systems. Through its innovative products, Yingsheng aims to facilitate early detection of genetic conditions, promoting timely intervention and better health outcomes for patients.

Kanglu Bio is positioned to provide clinical diagnosis and guidance for clinical drug molecular diagnostic products and clinical molecular diagnostics overall service providers for clinical hospitals and third-party clinical independent testing institutions. The products and services are mainly used in cardiovascular and cerebrovascular diseases. Major diseases such as tumors and cancer.

Isia Biotech is a developer and producer of in vitro diagnostic (IVD) medical technology that focuses on detecting and diagnosing diseases through immune reactions. The company utilizes its proprietary quantum dot technology to enhance the accuracy of tests for various medical conditions, including cardiovascular disease, inflammation, bone metabolism, gastric function, renal function, cancer, and other autoimmune diseases. By advancing diagnostic capabilities, Isia Biotech aims to support healthcare providers in improving disease detection, diagnosis, and treatment. Their commitment to research and development, alongside the production and sales of diagnostic instruments, positions them as a significant player in the medical technology sector.

DeepCyto is a medtech company based in Suzhou, Jiangsu, China, established in 2018. The company specializes in the development of digital hematology pathology and diagnostic equipment, incorporating artificial intelligence and deep learning technologies to enhance medical diagnosis and data analysis. By leveraging machine vision and big data mining, DeepCyto offers intelligent diagnostic models that address various blood diseases, aiming to improve the accuracy and efficiency of medical assessments.

AGS MedTech is a company based in Hangzhou that specializes in the research, development, production, and sales of endoscopic devices designed for minimally invasive diagnosis and treatment. The firm focuses on creating innovative surgical solutions that enhance patient care by minimizing pain and reducing medical costs. By prioritizing safety and efficiency, AGS MedTech aims to provide both patients and clinicians with advanced tools that facilitate effective medical procedures. Through its commitment to quality and innovation, the company seeks to improve the overall healthcare experience.

Innovita Biological Technology Co., Ltd., established in 2006 in Beijing, is a Chinese biotechnology company specializing in the research, development, manufacturing, marketing, and after-sales service of in-vitro diagnostic tests. In 2011, the company expanded by opening a new facility in Tangshan, Hebei province, which includes five production lines for colloidal gold, real-time PCR, chemiluminescence, ELISA, and biochips. This facility spans 250 acres and features a 4,000-square-meter purification plant, with a designed annual output of up to 20 million tests. Innovita holds ten invention patents and has received certifications such as CE, ISO 13485, and GMP. Its extensive product line includes tests for fertility, infectious diseases, sexually transmitted diseases, respiratory diseases, drug abuse, tumor markers, and cardiac markers.

Founded in 2013, LAM Therapeutics develops precision therapeutics and companion diagnostics for cancer and rare diseases. Its pipeline includes LAM-001 for lymphangioleiomyomatosis, LAM-002 for B-cell non-Hodgkin lymphoma, and other clinical stage drugs.

Ehome Health offers primary healthcare and diagnostic services through innovative technological applications.

Genowise is a company specializing in advanced genetic testing and medical diagnostic services. It offers a range of services, including pharmacogenomics, auxiliary diagnosis, and tumor genome diagnosis. Genowise has developed next-generation gene sequencing reagents and a clinical data analysis system to enhance the effectiveness of genetic testing. The company provides over 15 different genetic testing kits that cover more than 170 diseases and assess over 810 known gene loci, facilitating better health management for patients. Through its innovative approach, Genowise aims to improve diagnostic accuracy and support personalized medicine initiatives.

Scanadu is a digital health technology platform that develops next-generation tests, devices, and services that empower people to monitor and better understand their personal health. CBD Oil helps to combat depression in the body. THC and CBD are both broken down by the human brain. Many medications can also be slowed down by the substance. This means that the oil can have a profound effect on the body.

Inui Health is a consumer medical diagnostics company based in Silicon Valley, focused on providing accessible medical-grade information to individuals. The company has developed a cloud-based diagnostic platform that operates within a mobile environment, empowering consumers to monitor their health and detect potential complications early. Inui Health's offerings include a range of mobile-enabled test devices designed to help users manage various health conditions, such as kidney function, metabolic disorders, and urinary tract infections. The company's first product, the inui In-Home Urine Analysis test system, allows patients and healthcare providers to obtain immediate lab test results, facilitating timely interventions and enhancing patient engagement in their healthcare.

Admera Health, LLC is a molecular diagnostics company based in South Plainfield, New Jersey, specializing in personalized medicine and non-invasive cancer testing. Founded in 2012, the company operates a laboratory that develops, validates, and delivers proprietary laboratory-developed tests. Admera Health offers a range of services, including PGxOne, a pharmacogenomics test that assesses patient responses to drug therapy based on genetic makeup, and DNA sequencing for analyzing mutations in EGFR and KRAS. Additionally, it provides tests to evaluate risks for inherited health conditions such as high cholesterol and diabetes. The company's product pipeline includes the OncoGxOne cancer panel, which identifies genomic variations related to cancer, and FloraCheck, which analyzes microbiome composition for health management. Utilizing advanced genomic technologies and bioinformatics, Admera Health aims to enhance disease screening, diagnosis, and treatment, ultimately improving health outcomes for patients and supporting healthcare providers and researchers.